Mitochondrial Derived Reactive Oxygen Species on Cardiovascular Health in Chronic Obstructive Pulmonary Disease (COPD)

The Influence of Mitochondrial Derived Reactive Oxygen Species on Cardiovascular Health in Patients With Chronic Obstructive Pulmonary Disease

Status

Terminated

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05605548

Enrollment

Registered

2022-11-04

Start date

2023-02-16

Completion date

2024-07-30

Last updated

2025-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

MitoQ, vascular function, cardiovascular health, exercise intolerance, Mitochondria

Brief summary

Cardiovascular health is a critical problem in patients with chronic obstructive pulmonary disease (COPD). Existing literature suggests oxidative stress from the mitochondria c driving some of the poor health outcomes in COPD. MitoQ is a mitochondrial-targeted antioxidant that has shown promise in improving cardiovascular outcomes in similar populations. Thus the purpose of this study is to test if MitoQ can improve cardiovascular health in COPD.

Detailed description

In this study, a mitochondria-specific antioxidant will be compared to a placebo. Participants will be assigned randomly to receive either the antioxidant or the placebo for 6 weeks. A comprehensive assessment of cardiovascular health will be conducted before and after the administration of the supplement.

Interventions

DRUGMitoQ

MitoQ is a mitochondrial targeted antioxidant that can be obtained over-the-counter.

OTHERPlacebo

A look-alike inactive substance, a sugar pill

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

* Clinically diagnosed of COPD * Global Initiative for obstructive lung disease (GOLD) Stages II to IV

Exclusion criteria

* Forced Expiratory Volume in 1 second/ Functional Vital Capacity (FEV1/FVC) \>0.7 * Heart Disease * Diabetes * Vasoactive medications * Uncontrolled high blood pressure * Fluid in lungs * Sleep apnea * Raynaud's Phenomenon * Gangrene of the digits * History of coagulation * Pregnant women * Children

Design outcomes

Primary

Measure	Time frame	Description
Change in vascular function	Baseline and 6 weeks	Flow-mediated dilation will be used to measure vasodilation in the brachial artery
Change in Skeletal Muscle Oxygenation	Baseline and 6 weeks	Near-infrared spectroscopy will be used to measure leg muscle oxygenation
Change in oxidative stress	Baseline and 6 weeks	Blood draws will be taken to measure oxidative stress markers in the blood through electron paramagnetic resonance

Secondary

Measure	Time frame	Description
Change in arterial stiffness	Baseline and 6 weeks	Pulse wave velocity will be used to measure arterial stiffness.
Change in microvascular function	Baseline and 6 weeks	Microvascular function will be assessed using laser dopler imaging

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026